UK opens £20m fund for AI and VR addiction tech

If you teach health and social care or you’re studying how policy turns into practice, here’s a live case study. The government has opened a £20 million competition to speed up medicines, devices and digital tools that could reduce harm from drug and alcohol addiction. The Department of Health and Social Care published the call on 16 February 2026 and updated it on 19 February. (gov.uk)

The grants are delivered by Innovate UK under the Office for Life Sciences’ Addiction Healthcare Goals programme. Projects in wearables, virtual reality, treatment apps and AI sit alongside new medicines and medical devices, with the aim of improving treatment, strengthening recovery and saving lives. The press release underlines the scale: around 15,000 people die each year in the UK due to alcohol and drugs, with harms costing England an estimated £47 billion. (gov.uk)

Here’s how the scheme is structured. One strand supports late‑stage, near‑deployment projects with total project sizes up to £10 million to demonstrate real‑world effectiveness and UK market readiness. A second strand backs earlier‑stage innovation with awards up to £1.5 million to prove initial effectiveness and strengthen business planning. Both strands opened on 16 February and close on 6 May 2026. (gov.uk)

Ministers frame the move in practical terms. Health Minister Dr Zubir Ahmed says the goal is to use every tool that can ease suffering and aid recovery, while Science Minister Lord Vallance argues that supporting both mature technologies and earlier ideas creates a faster route from breakthrough to real‑world impact-and helps innovative UK companies grow. (gov.uk)

Quick explainer: how could AI, VR and wearables help in addiction care? AI tools can spot patterns linked to relapse and tailor support. Wearables can monitor breathing, heart rate or movement and trigger alerts, potentially preventing fatal overdoses. VR therapies can rehearse coping strategies for cravings in safe, simulated settings. Earlier AHG funding rounds have already supported wearables and sensor projects, AI‑enabled tools and VR‑based approaches, showing the kinds of ideas that can move through this pipeline. (iuk-business-connect.org.uk)

What counts as “service‑ready”? The late‑stage track expects projects to reach Technology Readiness Level 8 or 9, with necessary regulatory approvals and certification secured or actively in progress, plus a plan for manufacturing and UK rollout. By contrast, the earlier‑stage track looks for TRL 6 or 7, user acceptability in UK settings and a credible business plan pointing towards regulatory and certification milestones. (iuk-business-connect.org.uk)

Who can apply, in plain English. The earlier‑stage “Contracts for Innovation” awards can fund single applicants, including academia, research institutions and healthcare providers. The late‑stage “Advancing Innovation” awards are for industry‑led consortia, with variable grant levels and co‑funding depending on company size. If your college, university or local service partners with an SME, you can be part of a bid. (iuk-business-connect.org.uk)

Timing and the small print matter. Applications close on 6 May 2026. An applicant briefing webinar took place on 19 February 2026 (15:00–16:00) to walk through eligibility and scope. Successful projects will also be offered an education session run by the MHRA and NICE to clarify evidence expectations and the route to UK certification, approval and roll‑out. (iuk-business-connect.org.uk)

What this means for learners and educators. This competition is a chance to explore how health tech moves from idea to impact. You could map a patient pathway and ask: where would a wearable or an app genuinely help? You could debate risks and safeguards around data privacy, consent and equity. And you can follow a real funding timeline from call to close to see how teams build partnerships with the NHS and the third sector.

Media‑literacy check. A funding announcement is not a stamp of clinical approval; it’s an invitation to produce stronger evidence. Look for trials that show reduced relapse, fewer overdoses or better engagement-and for clear routes through MHRA regulation and NICE evaluation. If a product is described as “AI‑enabled” but the evidence is thin, ask what the model does, who it was trained on and how success is measured. The scheme is designed to make those answers clearer before anything reaches patients at scale. (iuk-business-connect.org.uk)